Genetically-Determined LDL Cholesterol and Risk of Subarachnoid Hemorrhage.
Sign Up to like & getrecommendations! Published in 2021 at "Annals of neurology"
DOI: 10.1002/ana.26250
Abstract: OBJECTIVE We evaluated whether genetically-elevated Low-Density Lipoprotein Cholesterol (LDL-C) levels are associated with lower risk of intracranial aneurysms and subarachnoid hemorrhage (IA/SAH). METHODS We conducted a two-sample Mendelian Randomization (MR) study. Our primary analysis used… read more here.
Keywords: risk; ldl; cholesterol; subarachnoid hemorrhage ... See more keywords
Low LDL-C levels are associated with risk of mortality in a Chinese cohort study
Sign Up to like & getrecommendations! Published in 2021 at "Endocrine"
DOI: 10.1007/s12020-021-02746-6
Abstract: Although low-density lipoprotein cholesterol (LDL-C) has been considered as a risk factor of atherosclerotic cardiovascular disease, limited studies can be available to evaluate the association of LDL-C with risk of mortality in the general population.… read more here.
Keywords: risk; risk mortality; ldl; ldl levels ... See more keywords
Diagnosis of familial hypercholesterolemia in a large cohort of Italian genotyped hypercholesterolemic patients.
Sign Up to like & getrecommendations! Published in 2022 at "Atherosclerosis"
DOI: 10.1016/j.atherosclerosis.2022.03.012
Abstract: BACKGROUND AND AIMS Familial hypercholesterolemia (FH) is the most relevant genetic cause of early cardiovascular disease (CVD). FH is suspected when low density lipoprotein cholesterol (LDL-C) levels exceed the 95th percentile of the population distribution.… read more here.
Keywords: dlcn; ldl levels; large cohort; dlcn score ... See more keywords
Elevated serum TC and LDL-C levels in Alzheimer’s disease and mild cognitive impairment: A meta-analysis study
Sign Up to like & getrecommendations! Published in 2020 at "Brain Research"
DOI: 10.1016/j.brainres.2019.146554
Abstract: Serum lipid levels such as triglyceride and cholesterol has been reported to play an important role in the pathophysiological process of Alzheimer disease (AD) and mild cognitive impairment (MCI). However, it still remains controversial in… read more here.
Keywords: serum ldl; levels smd; ldl; cognitive impairment ... See more keywords
ON-TREATMENT LDL-C LEVELS WHEN ALIROCUMAB DOSE IS DECREASED FROM 150 TO 75 MG EVERY 2 WEEKS IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM ODYSSEY OLE
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(17)35100-8
Abstract: Background: Alirocumab (ALI) is available in two doses, 75 and 150 mg (to be administered once every 2 weeks [Q2W]). ODYSSEY LONG TERM was a 78-week double-blind trial of ALI 150 mg Q2W versus placebo,… read more here.
Keywords: alirocumab dose; treatment ldl; every weeks; dose decreased ... See more keywords
Subcutaneous ICD noninferior to transvenous ICD
Sign Up to like & getrecommendations! Published in 2020 at "Nature Reviews Cardiology"
DOI: 10.1038/s41569-020-00440-0
Abstract: Many patients with homozygous familial hypercholesterolaemia (FH) do not reach guideline recommended levels of LDL cho lesterol (LDL C) with currently available therapies. A phase III trial now shows that treatment with evinacumab, a monoclonal… read more here.
Keywords: noninferior transvenous; transvenous icd; icd noninferior; placebo ... See more keywords
Effects of statins on all-cause mortality at different low-density-lipoprotein cholesterol levels in Asian patients with type 2 diabetes
Sign Up to like & getrecommendations! Published in 2018 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2018.1439829
Abstract: Abstract Objective: To investigate the effects of statins on all-cause mortality risk at different low-density lipoprotein cholesterol (LDL-C) levels, and to compare the mortality risk between statin users and non-users with identical LDL-C levels in… read more here.
Keywords: mortality risk; cause mortality; ldl; mortality ... See more keywords
What is the potential cardiovascular risk reduction associated with achieving LDL-C levels recommended in the ESC/EAS guidelines for very high-risk patients? Data from 18 European countries
Sign Up to like & getrecommendations! Published in 2020 at "European Heart Journal"
DOI: 10.1093/ehjci/ehaa946.3003
Abstract: For patients at very-high risk of cardiovascular (CV) events, the 2016 ESC/EAS dyslipidaemia guidelines recommended lipid-lowering therapy (LLT) to achieve an LDL-C level below 70 mg/dL. This was lowered to an LDL-C level below 55… read more here.
Keywords: reduction; risk; ldl level; ldl ... See more keywords
How low is safe? The frontier of very low (
Sign Up to like & getrecommendations! Published in 2021 at "European heart journal"
DOI: 10.1093/eurheartj/ehaa1080
Abstract: Low-density lipoprotein cholesterol (LDL-C) is a proven causative factor for developing atherosclerotic cardiovascular disease. Individuals with genetic conditions associated with lifelong very low LDL-C levels can be healthy. We now possess the pharmacological armamentarium (statins,… read more here.
Keywords: safe frontier; low safe; ldl; cholesterol ... See more keywords
Remnant cholesterol, LDL cholesterol and incident cardiovascular disease among Koreans: a national population-based study.
Sign Up to like & getrecommendations! Published in 2023 at "European journal of preventive cardiology"
DOI: 10.1093/eurjpc/zwad036
Abstract: BACKGROUND AND AIMS The synergistic association of remnant cholesterol (remnant-C) and low-density lipoprotein cholesterol (LDL-C) levels with incident cardiovascular disease (CVD) in various subgroups of Koreans was investigated. METHODS Using the national health insurance data,… read more here.
Keywords: remnant; remnant cholesterol; ldl levels; cvd ... See more keywords
2019 clinical trials in lipid lowering.
Sign Up to like & getrecommendations! Published in 2020 at "Current Opinion in Cardiology"
DOI: 10.1097/hco.0000000000000757
Abstract: PURPOSE OF REVIEW Lipid-lowering therapies play a major role in reducing atherosclerotic cardiovascular disease (ASCVD). This article reviews the most recent lipid-lowering therapy trials, many of which provide a unique opportunity to further reduce low-density… read more here.
Keywords: 2019 clinical; therapy; ldl levels; statin therapy ... See more keywords